Clinical utility of C-reactive protein in patients with ileal pouch anal anastomosis

Inflammatory Bowel Diseases

Volumn 16, Issue 10, 2010, Pages 1678-1684

  Lu, Hong ^b   Lian, Lei ^a   Navaneethan, Udayakumar ^a   Shen, Bo ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

C reactive protein; Disease activity; Ileal pouch; Restorative proctocolectomy

Indexed keywords

C REACTIVE PROTEIN;

ADULT; ARTICLE; CROHN DISEASE; DIAGNOSTIC ACCURACY; DISEASE ACTIVITY; ENDOSCOPY; FEMALE; HUMAN; ILEITIS; ILEOANAL ANASTOMOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY;

ADULT; ANASTOMOSIS, SURGICAL; C-REACTIVE PROTEIN; COLITIS, ULCERATIVE; COLONIC POUCHES; CROHN DISEASE; ENDOSCOPY, GASTROINTESTINAL; FEMALE; HUMANS; INFLAMMATION; MALE; POSTOPERATIVE COMPLICATIONS; POUCHITIS; PROCTOCOLECTOMY, RESTORATIVE; PROGNOSIS; PROSPECTIVE STUDIES; ROC CURVE;

EID: 78649271444     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21239     Document Type: Article

References (43)

1. Vermeire S, Van Assche G, Rutgeerts P,. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut. 2006; 55: 426-431.
2. Tillet WS, Francis T,. Serological reactions in pneumonia with a non-protein somatic fraction of the pneumococcus. J Exp Med. 1930; 52: 561-571.
3. Tall AR,. C-reactive protein reassessed. N Engl J Med. 2004; 350: 1450-1452.
4. Young B, Gleeson M, Cripps AW,. C-reactive protein: a critical review. Pathology. 1991; 23: 118-124.
5. Mortensen RF, Zhong W,. Regulation of phagocytic leukocyte activities by C-reactive protein. J Leukoc Biol. 2000; 67: 495-500.
6. Mortensen RF, Osmand AP, Lint TF, et al. Interaction of C-reactive protein with lymphocytes and monocytes: complement-dependent adherence and phagocytosis. J Immunol. 1976; 117: 774-781.
7. Saverymuttu SH, Hodgson HJ, Chadwick VS, et al. Differing acute phase responses in Crohn's disease and ulcerative colitis. Gut. 1986; 27: 809-813.
8. Henriksen M, Jahnsen J, Lygren I, et al. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study. Gut. 2008; 57: 1518-1523.
9. Linskens R, van Bodegraven A, Schoorl M, et al. Predictive value of inflammatory and coagulation parameters in the course of severe ulcerative colitis. Dig Dis Sci. 2001; 46: 644-648.
10. Moran A, Jones A, Asquith P,. Laboratory markers of colonoscopic activity in ulcerative colitis and Crohn's colitis. Scand J Gastroenterol. 1995; 30: 356-360.
11. Schunk K, Kern A, Oberholzer K, et al. Hydro-MRI in Crohn's disease: appraisal of disease activity. Invest Radiol. 2000; 35: 431-437. (Pubitemid 30448171)
12. Gomes P, du Boulay C, Smith C, et al. Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut. 1986; 27: 92-95.
13. Solem CA, Loftus EV Jr, Tremaine WJ, et al. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis. 2005; 11: 707-712.
14. Targan SR, Feagan BG, Fedorak RN, et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE trial. Gastroenterology. 2007; 132: 1672-1683.
15. Sandborn W, Feagan B, Radford-Smith G, et al. CDP571, a humanized monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial. Gut. 2004; 53: 1485-1493.
16. Fazio VW, Ziv Y, Church JM, et al. Ileal pouch-anal anastomosis: complications and function in 1005 patients. Ann Surg. 1995; 222: 120-127.
17. Sandborn WJ,. Pouchitis following ileal pouch-anal anastomosis: definition, pathogenesis, and treatment. Gastroenterology. 1994; 107: 1856-1860.
18. Coffey JC, Winter DC, Neary P, et al. Quality of life after ileal pouch-anal anastomosis: an evaluation of diet and other factors using the Cleveland Global Quality of Life instrument. Dis Colon Rectum. 2002; 45: 30-38.
19. Shen B, Fazio VW, Remzi FH, et al. Comprehensive evaluation of inflammatory and non-inflammatory sequelae of ileal pouch-anal anastomosis. Am J Gastroenterol. 2005; 100: 93-101.
20. Navaneethan U, Shen B,. Laboratory tests for patients with ileal pouch-anal anastomosis: clinical utility in predicting, diagnosing, and monitoring pouch disorders. Am J Gastroenterol. 2009; 104: 2606-2615.
21. Thomas P, Rihani H, RÃseth A, et al. Assessment of ileal pouch inflammation by single stool calprotectin assay. Dis Colon Rectum. 2000; 43: 214-220.
22. Johnson MW, Maestranzi S, Duffy AM, et al. Fecal calprotectin: a noninvasive diagnostic tool and marker of severity in pouchitis. Eur J Gastroenterol Hepatol. 2008; 20: 174-179.
23. Parsi M, Shen B, Achkar J, et al. Fecal lactoferrin for diagnosis of symptomatic patients with ileal pouch-anal anastomosis. Gastroenterology. 2004; 126: 1280-1286. (Pubitemid 38552792)
24. Lim M, Gonsalves S, Thekkinkattil D, et al. The assessment of a rapid noninvasive immunochromatographic assay test for fecal lactoferrin in patients with suspected inflammation of the ileal pouch. Dis Colon Rectum. 2008; 51: 96-99.
25. Kuisma J, Nuutinen H, Luukkonen P, et al. Long term metabolic consequences of ileal pouch-anal anastomosis for ulcerative colitis. Am J Gastroenterol. 2001; 96: 3110-3116.
26. Shen B, Achkar JP, Connor JT, et al. Modified pouchitis disease activity index: a simplified approach to the diagnosis of pouchitis. Dis Colon Rectum. 2003; 46: 748-753
27. Sandborn WJ, Tremaine WJ, Batts KP, et al. Pouchitis after ileal pouch-anal anastomosis: a Pouchitis Disease Activity Index. Mayo Clin Proc. 1994; 69: 409-415.
28. Fefferman DS, Farrell RJ,. Endoscopy in inflammatory bowel disease: indications, surveillance, and use in clinical practice. Clin Gastroenterol Hepatol. 2005; 3: 11-24.
29. Shen B, Achkar J-P, Lashner BA, et al. Endoscopic and histologic evaluations together with symptom assessment are required to diagnose pouchitis. Gastroenterology. 2001; 121: 261-267.
30. Parsi MA, Ellis JJ, Lashner BA,. Cost-effectiveness of quantitative fecal lactoferrin assay for diagnosis of symptomatic patients with ileal pouch-anal anastomosis. J Clin Gastroenterol. 2008; 42: 799-805.
31. Poullis AP, Zar S, Sundaram KK, et al. A new, highly sensitive assay for C-reactive protein can aid the differentiation of inflammatory bowel disorders from constipation and diarrhoea-predominant functional bowel disorders. Eur J Gastroenterol Hepatol. 2002; 14: 409-412.
32. Shine B, Berghouse L, Jones JE, et al. C-reactive protein as an aid in the differentiation of functional and inflammatory bowel disorders. Clin Chim Acta. 1985; 148: 105-109.
33. Langhorst J, Elsenbruch S, Koelzer J, et al. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol. 2008; 103: 162-169.
34. Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin correlates more closely with the simple endoscopic score for Crohn's Disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol. 2010; 105: 162-169.
35. FrÃslie KF, Jahnsen J, Moum BA, et al and the IBSEN Group. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology. 2007; 133: 412-422.
36. Rutgeerts P, Diamond RH, Bala M, et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc. 2006; 63: 433-442.
37. Rutgeerts P, Vermeire S, Van Assche G,. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Gut. 2007; 56; 453-455.
38. Schnitzler F, Fidder H, Ferrante M, et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis. 2009; 15: 1295-1301.
39. Fagan EA, Dyck RF, Maton PN, et al. Serum levels of C-reactive protein in Crohn's disease and ulcerative colitis. Eur J Clin Invest. 1982; 12: 351-359.
40. Pepys MB, Druguet M, Klass HJ, et al. Immunological studies in inflammatory bowel disease. Ciba Found Symp. 1977; 46: 283-304.
41. Greenfield JR, Samaras K, Jenkins AB, et al. Obesity is an important determinant of baseline serum C-reactive protein concentration in monozygotic twins, independent of genetic influences. Circulation. 2004; 109: 3022-3028.
42. Maachi M, Pieroni L, Bruckert E, et al. Systemic low-grade inflammation is related to both circulating and adipose tissue TNF alpha, leptin and IL-6 levels in obese women. Int J Obes Relat Metab Disord. 2004; 28: 993-997.
43. Carlson CS, Aldred SF, Lee PK, et al. Polymorphisms within the C-reactive protein (CRP) promoter region are associated with plasma CRP levels. Am J Hum Genet. 2005; 77: 64-67.